CN108272917A - A kind of Uygur medicine composition and preparation method thereof for treating failure of memory - Google Patents
A kind of Uygur medicine composition and preparation method thereof for treating failure of memory Download PDFInfo
- Publication number
- CN108272917A CN108272917A CN201810268476.1A CN201810268476A CN108272917A CN 108272917 A CN108272917 A CN 108272917A CN 201810268476 A CN201810268476 A CN 201810268476A CN 108272917 A CN108272917 A CN 108272917A
- Authority
- CN
- China
- Prior art keywords
- medicine composition
- preparation
- uygur medicine
- uygur
- memory
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 71
- 239000000203 mixture Substances 0.000 title claims abstract description 45
- 230000015654 memory Effects 0.000 title claims abstract description 41
- 238000002360 preparation method Methods 0.000 title claims abstract description 30
- 235000004204 Foeniculum vulgare Nutrition 0.000 claims abstract description 34
- 241000220317 Rosa Species 0.000 claims abstract description 17
- 240000006365 Vitis vinifera Species 0.000 claims abstract description 17
- 235000014787 Vitis vinifera Nutrition 0.000 claims abstract description 17
- 235000013211 Adiantum capillus veneris Nutrition 0.000 claims abstract description 15
- 244000005852 Adiantum capillus veneris Species 0.000 claims abstract description 15
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims abstract description 14
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 14
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims abstract description 14
- 229940010454 licorice Drugs 0.000 claims abstract description 14
- 239000002994 raw material Substances 0.000 claims abstract description 10
- 241000212314 Foeniculum Species 0.000 claims description 32
- 239000000284 extract Substances 0.000 claims description 27
- 239000000341 volatile oil Substances 0.000 claims description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 24
- 239000000843 powder Substances 0.000 claims description 21
- 238000000605 extraction Methods 0.000 claims description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 15
- 239000007788 liquid Substances 0.000 claims description 15
- 241000202807 Glycyrrhiza Species 0.000 claims description 13
- 238000001914 filtration Methods 0.000 claims description 13
- 239000000706 filtrate Substances 0.000 claims description 12
- 239000002245 particle Substances 0.000 claims description 10
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 9
- 239000002775 capsule Substances 0.000 claims description 9
- 239000008187 granular material Substances 0.000 claims description 9
- 229940100688 oral solution Drugs 0.000 claims description 9
- 239000006187 pill Substances 0.000 claims description 9
- 239000006188 syrup Substances 0.000 claims description 9
- 235000020357 syrup Nutrition 0.000 claims description 9
- 239000003826 tablet Substances 0.000 claims description 9
- 235000019441 ethanol Nutrition 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 7
- 230000008569 process Effects 0.000 claims description 7
- 230000001954 sterilising effect Effects 0.000 claims description 7
- 229920000858 Cyclodextrin Polymers 0.000 claims description 6
- 239000001116 FEMA 4028 Substances 0.000 claims description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 6
- 239000006286 aqueous extract Substances 0.000 claims description 6
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims description 6
- 229960004853 betadex Drugs 0.000 claims description 6
- 239000012153 distilled water Substances 0.000 claims description 6
- 239000012535 impurity Substances 0.000 claims description 6
- 239000008101 lactose Substances 0.000 claims description 6
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 6
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 6
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 6
- 238000010992 reflux Methods 0.000 claims description 6
- 239000000243 solution Substances 0.000 claims description 6
- 238000005469 granulation Methods 0.000 claims description 5
- 230000003179 granulation Effects 0.000 claims description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 4
- 239000006228 supernatant Substances 0.000 claims description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 3
- 235000018142 Hedysarum alpinum var americanum Nutrition 0.000 claims description 3
- 240000006461 Hedysarum alpinum var. americanum Species 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 238000005119 centrifugation Methods 0.000 claims description 3
- 238000004140 cleaning Methods 0.000 claims description 3
- 239000006071 cream Substances 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 239000000469 ethanolic extract Substances 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 229920006395 saturated elastomer Polymers 0.000 claims description 3
- 239000011122 softwood Substances 0.000 claims description 3
- 238000001694 spray drying Methods 0.000 claims description 3
- 238000004659 sterilization and disinfection Methods 0.000 claims description 3
- 235000020985 whole grains Nutrition 0.000 claims description 3
- 230000001476 alcoholic effect Effects 0.000 claims description 2
- 238000004821 distillation Methods 0.000 claims description 2
- 229910052742 iron Inorganic materials 0.000 claims description 2
- 239000013065 commercial product Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 abstract description 10
- 208000024827 Alzheimer disease Diseases 0.000 abstract description 6
- 230000007423 decrease Effects 0.000 abstract description 5
- 230000000694 effects Effects 0.000 abstract description 4
- 230000001225 therapeutic effect Effects 0.000 abstract description 2
- 240000006927 Foeniculum vulgare Species 0.000 abstract 2
- 240000004670 Glycyrrhiza echinata Species 0.000 abstract 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 33
- 238000011282 treatment Methods 0.000 description 22
- 230000002159 abnormal effect Effects 0.000 description 21
- 201000010099 disease Diseases 0.000 description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 16
- 206010062717 Increased upper airway secretion Diseases 0.000 description 12
- 208000026435 phlegm Diseases 0.000 description 12
- 229940079593 drug Drugs 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 9
- 230000032683 aging Effects 0.000 description 8
- 230000002265 prevention Effects 0.000 description 8
- 230000009182 swimming Effects 0.000 description 8
- 238000012347 Morris Water Maze Methods 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 238000003304 gavage Methods 0.000 description 4
- 238000012549 training Methods 0.000 description 4
- 206010012289 Dementia Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000007087 memory ability Effects 0.000 description 3
- 210000003097 mucus Anatomy 0.000 description 3
- 238000010175 APPswe/PSEN1dE9 Methods 0.000 description 2
- 208000026139 Memory disease Diseases 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 230000019771 cognition Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000013480 data collection Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 230000036651 mood Effects 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000003950 pathogenic mechanism Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 208000000044 Amnesia Diseases 0.000 description 1
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 description 1
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- 206010010297 Confabulation Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 206010033848 Paramnesia Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 206010065954 Stubbornness Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 235000019606 astringent taste Nutrition 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 230000007278 cognition impairment Effects 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000037456 inflammatory mechanism Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000006403 short-term memory Effects 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
- A61K36/12—Filicopsida or Pteridopsida
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/235—Foeniculum (fennel)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/738—Rosa (rose)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to field of traditional Chinese, it is related to a kind of Uygur medicine composition and preparation method thereof for treating failure of memory, the Uygur medicine composition is made of the raw material of following weight proportion, 60~150 g of foreign fennel, 60~160 g of fennel seeds, 60~360 g of raisins, 60~160 g of rose, 60~160 g of 60~160 g of fig, 60~160 g of licorice and venushair fern.The present invention to the patients such as Alzheimer disease, depression and memory of the elder decline symptom have certain therapeutic effect, have clear improvement failure of memory the effect of.
Description
Technical field
The invention belongs to field of traditional Chinese, it is related to a kind of Uygur medicine composition that treating failure of memory and its preparation
Method.
Background technology
Memory is brain to the identification of things, memorize, holding, reproduces or re-recognize, it be carry out thinking, think about it etc. it is advanced
It is movable basic., there are depression, anxiety disorder, aging, insomnia, excessive pressure at heart in the main reason for failure of memory.Year therewith
The growth decrease of memory in age is one of the performance that person in middle and old age's body function weakens.
Alzheimer disease (Alzheimer ' s disease, AD) is a kind of nervous system degenerative disease by a variety of
Memory caused by reason and cognition dysfunction and nervous function are damaged as main feature.AD is most common geriatric disease,
It is also received significant attention [2] in aging society.With AD progress of research, the early symptom of AD is especially grasped and identified,
Early treatment, early intervention become the key measure of AD prevention and treatment.Be directed in recent years the teiology of AD, pathology and
Relevant molecular biology research has unprecedented progress.As that studies AD gos deep into, it is found that number of mechanisms may be with
The morbidity of AD is related.Research thinks that the possibility pathomechanism of AD has central neurotransmitter metabolic disorder, energetic supersession disorderly at present
Unrest, amyloid metabolism exception, cytoskeleton deformation, nerve cell apoptosis, radical damage, inflammatory mechanisms etc..With generation
Within the scope of boundary, the especially continuous development of Chinese population aging trend, prevention this world's sex medicine project of AD China
As one of the hot issue of research.The drug therapy of AD is very rare, at present common drug can only symptomatic treatment, do not solve
Basic prevention and treatment problem, morbidity complex disease associated with many factors, Chinese traditional treatment as AD may be
A kind of advantage.The common Western medicine for the treatment of AD has Secretase inhibitors, the nonsteroidal anti-inflammatory that anticholinesterase, anti-A β are treated
Medicine, Nerve growth factors drug etc., but these treatment AD drugs there is no any type that can completely effectively treat AD.Chinese medicine
The research of medicine prevention AD, which also obtains certain achievement, especially herbal mixture, has the function of the integrated regulation of multipath, has single
The characteristic and advantage of all no advantage of one herbaceous plant and traditional Chinese medicine prevention AD.
Uygur's medicine（Hereinafter referred to as dimension doctor）It is the important component of traditional Chinese medicine and diligent Uygur
The wisdom of the clansman people is succinct, has abundant clinical experience and unique theoretical system.Can perfect preservation be also till now
One miracle.AD belongs to the scopes such as " forgetful ", " forgetting " caused by abnormal humour in dimension doctor in dimension doctor's ancient books.In dimension doctor ancient times doctor
Learning has largely etiology and pathogenesis, symptom and sign and the prevention etc. of diseases such as " memory loss " " insomnia " " foolishness " " forgettings " in document
Description and record.Dimension doctor thinks that abnormal phlegm is the important pathologic basis of AD morbidities, in the mild cognition impairment of early stage
Phase, abnormal phlegm often account for main status in clinical manifestation.Research finds the AD occurred in the abnormal mucus cross-examination stage
Symptoms are mild, clinical to use abnormal phlegm maturing agent first, secondly with medicine prevention AD is cured mainly, can obtain good therapeutic effect.Dimension doctor
Think that brain is raw property internal organs, mucilaginous substance attribute be also it is raw, wherein astringent taste mucilaginous substance be mixed among mucus it is atrabiliary
Abnormal humour, heavy weight, quality is thick, is precipitated in the brain as brain pathological product, is easy to form nerve block, from different ways
Diameter and/or the normal physiological function for influencing destruction nerve fiber in varying degrees, influencing cell.Abnormal phlegm change is AD
The early stage basic interpretation of the cause, onset and process of an illness, and the immediate cause in AD morbidities.Memory disorder AD patient symptom outstanding.Occur earliest
It is decrease of memory, and then occurs forgeing the major event crossed of past experience or vital task, paramnesia and confabulation fabrication and many
See.Early stage mainly involves short term memory, and memory retention and studying new knowledge are known difficult.With progression of the disease, gradually involve note at a specified future date
Recall.
Depression is a kind of common phrenoblabia, can be caused by a variety of causes, and mild depression is low with lasting mood
It falls and is characterized.It is depressed, gloomy, dejected in terms of mood, interest is lacked to daily routines, to future pessimism, before sick
Mental wound often illegally occupy in brain so that lassitude, mental retardation, patient withers thus and compunction.In cognition side
Face, attention can not be concentrated, and memory reduces, retardation of thinking.
Dimension doctor is used as traditional medicine, is not only dedicated to the treatment of disease, but also more pays close attention to the prevention of disease.Currently, doctor
Many problems of educational circles all hope by means of power in traditional medicine multiple target point intervention find breach, AD treatment Forward but also
Dimension medicine obtains the chance to stand on the same starting line with Western medicine.Uygur's medicine is selected according to etiology and pathogenesis has ripe exception
The complex diseases such as mucilaginous substance body fluid prescription prevention dementia are the concentration bodies that dimension cures that body fluid opinion, diagnosis and treatment, prescription are gained knowledge
It is existing.It is worth noting that by being applied to the preliminary stage of AD clinical symptoms not yet occur with ripe abnormal phlegm prescription, it can
To effectively inhibit or disease is prevented further to deteriorate, generated newly by " burning " if treatment abnormal phlegm cannot be carried out in time
Morbid substance abnormal savda, such disease stubbornness is refractory.Therefore it is considered that when abnormal mucus cross-examination stage of AD is anti-
It is most critical to control AD, it is believed that ripe abnormal phlegm prescription can make AD treatment Forwards.Clinically to by extremely viscous
In the treatments of complex diseases such as aging and associated AD caused by liquid matter, ripe abnormal phlegm is used respectively first
Prescription improves abnormal humour（The quality of abnormal humour or quantity lacked of proper care are adjusted）And accumulation（It will be adjusted
The abnormal humour of reason is gathered in intestinal mucosa, blood and tissue space etc., convenient for discharge）, corresponding scavenger is then used, is made
Ripe good abnormal humour excretes, and to make unbalance makings restore, isohydria establishes base for this dirty treatment
Plinth.Foundation Uygur medicine " the different same machine of disease " and " with card Tongfang " theory, especially Alzheimer disease early stage, depression, 2 types
In the disease treatments such as diabetes and aging, using have effects that mucilaginous substance from ripe compound medicine to failure of memory symptom into
Row treatment.
The Uygur medicine composition for the treatment of failure of memory provided by the present invention is according to Uygur's medicine basic theory
With prescription theory by foreign fennel, fennel seeds, raisins, rose, fig, licorice and with Uygur's medicinal material such as venushair fern
Compound preparation is formed, pharmacological property is xeothermic, and the ripe abnormal phlegm body fluid of energy adjusts raw makings, is clinically mainly used for A Erci
The treatment of the diseases failure of memory symptoms such as the silent disease in sea, depression, diabetes B and aging.It is the study found that originally by animal
Uygur medicine composition in invention has the function of enhancing learning and memory of little mouse power very well, i.e., the combination of above-mentioned enhancing memory
Object is preparing the application in enhancing memory drug.The present invention meets the theoretical pathogenic mechanism of Uygur medicine failure of memory
It learns, Formulation is reasonable, and compatibility is rigorous, can be applied in the drug, health products and food for improving memory.
In clinical test, the Uygur medicine composition extract for the treatment of failure of memory provided by the present invention obviously changes
The kind learning memory ability and spatial search capability for improving Alzheimer disease mouse.Clinically it is mainly used for Alzheimer
The treatment of the diseases failure of memory symptom such as disease, depression, diabetes B and aging.
The Uygur medicine composition for the treatment of failure of memory provided by the present invention is used to improve the drug of memory, health products
With the purposes in food.
Invention content
It is right the purpose of the present invention is to provide a kind of Uygur medicine composition and preparation method thereof for treating failure of memory
The diseases failure of memory symptom such as Alzheimer disease, depression, diabetes B and aging has effects that the one of certain curative effect
Kind treats Uygur medicine composition of failure of memory and preparation method thereof.
The object of the present invention is achieved like this：A kind of Uygur medicine composition that treating failure of memory and its preparation side
Method, it is characterised in that：The Uygur medicine composition be made of the raw material of following weight proportion, 60~150 g of foreign fennel,
60~160 g of fennel seeds, 60~360 g of raisins, 60~160 g of rose, 60~160 g of fig, licorice 60~160
60~160 g of g and venushair fern；The Uygur medicine composition be made of the raw material of following weight proportion, 60 g of foreign fennel,
60 g of fennel seeds, 60 g of raisins, 111 g of rose, 60 g of 238 g of fig, 160 g of licorice and venushair fern；The dimension
I you drug composition is 111 g of foreign fennel, 111 g of fennel seeds, 238 g of raisins made of the raw material of following weight proportion,
105 g of rose, 111 g of 150 g of fig, 105 g of licorice and venushair fern.
The formula of the Uygur medicine composition and its extract pharmaceutically acceptable preparation is particle, syrup, cream
Side, oral solution, tablet, powder, capsule, granule and pill.
Preparation method：The Uygur medicine composition is prepared with two methods, is as follows：1）Water extracting method：
1. weighing appropriate foreign fennel, fennel seeds, raisins, the medicines such as rose, fig, licorice and venushair fern according to aforementioned proportion
Material in extraction vessel plus is equivalent to the distilled water of 10 times of medicine materical crude slice weight, impregnates 30 minutes；2. decocting extraction twice, decoct for the first time
Boil extraction 60 minutes, filtering；The distilled water for adding 5 times of suitable medicine materical crude slice weight for the second time extracts filtering in 30 minutes；3. merging filtrate
Concentration, crushes granulation at spray drying；4. preparation is particle, syrup, herbal paste, oral solution, tablet, powder, capsule, granule
And pill.2）Essential oil extraction method：1. taking foreign fennel and appropriate fennel seeds respectively according to the above ratio, adds 5 ~ 15 times of amount water, steam
Evaporate method extraction volatile oil 5 ~ 10 hours, after volatile oil extracting, remaining Aqueous extracts filtering, filtrate is collected spare；2. volatilizing
Oil is saturated with beta-cyclodextrin, refrigerated overnight, is filtered, dry, finely ground, crosses 80 ~ 100 mesh sieve, spare；3. dividing according to the above ratio
Do not take raisins, rose and appropriate fig, be suitably ground into coarse powder, add 5 ~ 15 times amount water, refluxing extraction 1 ~ 3 time, every time
Extraction 1 ~ 3 hour, filtering, merging filtrate are concentrated under reduced pressure, and supercentrifugal process removal of impurities takes supernatant, spare；4. according to the above ratio
Extracting liquorice root, appropriate venushair fern are suitably ground into coarse powder respectively, add the ethyl alcohol of 5 ~ 15 times of amounts a concentration of 55 ~ 85%, refluxing extraction 1
It ~ 3 times, extracts 1 ~ 3 hour every time, filtering, merging filtrate is spare；5. remaining aqueous solution after volatile oil will be extracted in second,
Supernatant after cleaning in third step, liquid extract is concentrated under reduced pressure into ethanol extract respectively in the 4th step, merges liquid extract, positive empty
Main officer of Tibet is early, crushes, and crosses 80 ~ 100 mesh sieve, obtains extract powder, spare；6. appropriate extract powder and volatile oil saturate and lactose mixing are taken,
The softwood processed in right amount of 90% ethanol solution containing 5% polyvinylpyrrolidone is added, is sieved and is pelletized with 14 mesh, it is true at a temperature of 55 ~ 65 DEG C
Sky is dry, whole grain, sterilizing；7. preparation is particle, syrup, herbal paste, oral solution, tablet, powder, capsule, granule and pill.
Used beta-cyclodextrin, lactose, polyvinylpyrrolidone, ethyl alcohol be as《Chinese Pharmacopoeia》Defined commercially available production
Product；
Used volatile oil saturation conditions β-CD：Volatile oil proportioning is 4:1~8:1, saturation temperature is 30 ~ 45 DEG C, saturation time 1 ~
3 hours；Volatile oil saturate drying temperature is 38 ~ 42 DEG C；Institute is concentrated under reduced pressure into medicinal material using Aqueous extracts:Liquid ratio is 1:3~
1:10；Centrifuge speed is 10000 ~ 12000 revs/min when used supercentrifugal process removal of impurities, and centrifugation time is 10 ~ 20 points
Clock；The temperature that is concentrated under reduced pressure using each extracting solution be 60 ~ 75 DEG C, pressure is -0.09 ~ -0.07pa, and being concentrated into relative density is
1.20 ~ 1.25 liquid extract；Institute is to use 60Co- gamma-rays 6kGy irradiation sterilizations using sterilizing methods.
Specific implementation mode
With reference to embodiment, the invention will be further described：
A kind of Uygur medicine composition and preparation method thereof for treating failure of memory, it is characterised in that：The Uygur medicine group
Close object be made of the raw material of following weight proportion, 60~150 g of foreign fennel, 60~160 g of fennel seeds, raisins 60~
360 g, 60~160 g of rose, 60~160 g of 60~160 g of fig, 60~160 g of licorice and venushair fern；The dimension
My your drug composition is 60 g of foreign fennel, 60 g of fennel seeds, 60 g of raisins made of the raw material of following weight proportion, rose
It is rare to spend 111 g, 60 g of 238 g of fig, 160 g of licorice and venushair fern；The Uygur medicine composition is by following weight
Made of the raw material of proportioning, 111 g of foreign fennel, 111 g of fennel seeds, 238 g of raisins, 105 g of rose, fig 150
G, 111 g of 105 g of licorice and venushair fern.
The formula of the Uygur medicine composition and its extract pharmaceutically acceptable preparation is particle, syrup, cream
Side, oral solution, tablet, powder, capsule, granule and pill.
The Uygur medicine composition is prepared with two methods, is as follows：
First method：Water extracting method
The first step：Appropriate foreign fennel, fennel seeds, raisins, rose, fig, licorice and iron are weighed according to aforementioned proportion
The medicinal materials such as line fern in extraction vessel plus are equivalent to the distilled water of 10 times of medicine materical crude slice weight, impregnate 30 minutes；
Second step：It decocts extraction twice, decocts extraction 60 minutes, filtering for the first time；5 times of suitable medicine materical crude slice weight is added for the second time
Distilled water is extracted 30 minutes and is filtered；
Third walks：Merging filtrate concentration, crushes granulation at spray drying；
4th step：Preparation is particle, syrup, herbal paste, oral solution, tablet, powder, capsule, granule and pill.
Second method：Essential oil extraction method
The first step：Take foreign fennel and appropriate fennel seeds respectively according to the above ratio, add 5 ~ 15 times amount water, the way of distillation extract volatile oil 5 ~
10 hours, after volatile oil extracting, remaining Aqueous extracts filtering, filtrate was collected spare；
Second step：Volatile oil is saturated with beta-cyclodextrin, refrigerated overnight, is filtered, dry, finely ground, crosses 80 ~ 100 mesh sieve, standby
With；
Third walks：It takes raisins, rose and appropriate fig respectively according to the above ratio, is suitably ground into coarse powder, add 5 ~ 15 times
Water is measured, refluxing extraction 1 ~ 3 time is extracted 1 ~ 3 hour every time, filtering, and merging filtrate is concentrated under reduced pressure, and supercentrifugal process removal of impurities takes
Clear liquid, it is spare；
4th step：Extracting liquorice root is distinguished according to the above ratio, and appropriate venushair fern is suitably ground into coarse powder, adds 5 ~ 15 times of amounts a concentration of
55 ~ 85% ethyl alcohol, refluxing extraction 1 ~ 3 time are extracted 1 ~ 3 hour every time, filtering, and merging filtrate is spare；
5th step：Remaining aqueous solution after volatile oil, the supernatant after cleaning in third step, in the 4th step will be extracted in second
Liquid extract is concentrated under reduced pressure into ethanol extract respectively, merges liquid extract, positive sky main officer of Tibet is early, crushes, and crosses 80 ~ 100 mesh sieve, obtains medicinal extract
Powder, it is spare；
6th step：Appropriate extract powder and volatile oil saturate and lactose mixing are taken, 90% second containing 5% polyvinylpyrrolidone is added
Softwood processed is dried in vacuo, whole grain at a temperature of 55 ~ 65 DEG C, is sterilized with the sieve granulation of 14 mesh alcoholic solution in right amount；
7th step：Preparation is particle, syrup, herbal paste, oral solution, tablet, powder, capsule, granule and pill.
Used beta-cyclodextrin, lactose, polyvinylpyrrolidone, ethyl alcohol be as《Chinese Pharmacopoeia》Defined commercially available production
Product.
Used volatile oil saturation conditions β-CD：Volatile oil proportioning is 4:1~8:1, saturation temperature is 30 ~ 45 DEG C, when saturation
Between 1 ~ 3 hour.
Volatile oil saturate drying temperature is 38 ~ 42 DEG C；Institute is concentrated under reduced pressure into medicinal material using Aqueous extracts:Liquid ratio is 1:
3~1:10。
Centrifuge speed is 10000 ~ 12000 revs/min when used supercentrifugal process removal of impurities, and centrifugation time is 10 ~ 20
Minute.
The temperature that is concentrated under reduced pressure using each extracting solution be 60 ~ 75 DEG C, pressure is -0.09 ~ -0.07pa, is concentrated into opposite
The liquid extract that density is 1.20 ~ 1.25.
Institute is to use 60Co- gamma-rays 6kGy irradiation sterilizations using sterilizing methods.
Pharmacodynamic study
Test method.
Animal packet and dosage regimen.
It is right to be randomly divided into model control group, the positive according to mouse weight for APP/PS1 double transgenics model mice 72
According to group with the high, medium and low dosage group of composition water extract, every group 12.It is small with the identical C57BL/6J of same monthly age genetic background
Mouse is as Normal group, every group 10.According to the clinical application course for the treatment of and dosage of abnormal phlegm maturing agent determine mouse to
Medicine number of days and dosage, i.e. low, middle and high dose groups press 1.50,3.0,6.0 gkg respectively-1·d-1Gavage abnormal phlegm is ripe
Agent, 6 totally months；Normal group and model control group gavage physiological saline, 6 totally months.All experimental animals are equal during experiment
Free water, normal diet.
Morris water maze laboratories.
It is 2 days trained in advance with the test of MT -200 Morris water maze video tracking analysis systems, mouse, 3 times a day,
Per two hours of minor tick, mouse is entered pond in different quadrants towards wall at random, and order is different daily, guides it by rectilinear direction
It swims to platform and stands 20 seconds on platform, take out underproof mouse later, remaining mouse is started just by 6 original groups
Formula is tested.
The method that sequence is tested with reference to Morris etc. carries out, and test includes：（1）Orientation navigation experiment（place
navigation）, for measuring mouse to water maze learning and memory ability, that is, record incubation period.It continue for five days, first day
There is no platform in pond, makes mouse free swimming 60 seconds in pond, have acclimatization training.One is randomly choosed in training in four days
A quadrant by mouse towards pool wall into the water, force mouse study find be set to water surface platform below.60 are recorded in computer
It it is incubation period the time required to finding platform in second.If failing to find platform in 60 seconds, platform can be directed it to and in platform
It stops 20 seconds, incubation period is recorded as 60 seconds.Data collection and processing are completed by Morris water maze system softwares.
Orientation navigation experiment.
In the experiment of mouse Morris four days orientation navigations of water maze, all mouse reach latency and the trip of platform
Swimming distance is gradually shortened.The escape latency and swimming distance of the high, medium and low dosage group mouse of composition water extract are in decline
Trend.For Model of Dementia group compared with the high, medium and low dosage group mouse escape latency of extract and swimming distance, difference has statistics
Learn meaning（P＜ 0.05）.
The comparison of 1 each group mouse escape latency of table（S）（n=10）
Note：Compared with normal group,△ P＜ 0.01；Compared with model group, *P0.05 * * of ＜P＜ 0.01
As long as using the pharmacodynamic study for making particle after modern times technology
Experimental method.
Animal packet and dosage regimen.
APP/PS1 double transgenics model mice 72, according to mouse weight with being divided into model control group, positive control
Group and the high, medium and low dosage group of composition grain, every group 12.Using the identical C57BL/6J mouse of same monthly age genetic background as
Normal group, every group 10.Mouse administration number of days and dosage are determined according to according to the clinical application course for the treatment of and dosage of composition,
I.e. low, middle and high dose groups press 1.0,2.0,4.0 gkg respectively-1·d-1Gavage abnormal phlegm maturing agent, 6 totally months；Just
Normal control group and model control group gavage physiological saline, 6 totally months.All equal free waters of experimental animal during experiment, normally
Diet.
Morris water maze laboratories.
It is 2 days trained in advance with the test of MT -200 Morris water maze video tracking analysis systems, mouse, 3 times a day,
Per two hours of minor tick, mouse is entered pond in different quadrants towards wall at random, and order is different daily, guides it by rectilinear direction
It swims to platform and stands 20 seconds on platform, take out underproof mouse later, remaining mouse is started just by 6 original groups
Formula is tested.
The method that sequence is tested with reference to Morris etc. carries out, and test includes：（1）Orientation navigation experiment（place
navigation）, for measuring mouse to water maze learning and memory ability, that is, record incubation period.It continue for five days, first day
There is no platform in pond, makes mouse free swimming 60 seconds in pond, have acclimatization training.One is randomly choosed in training in four days
A quadrant by mouse towards pool wall into the water, force mouse study find be set to water surface platform below.60 are recorded in computer
It it is incubation period the time required to finding platform in second.If failing to find platform in 60 seconds, platform can be directed it to and in platform
It stops 20 seconds, incubation period is recorded as 60 seconds.Data collection and processing are completed by Morris water maze system softwares.
Orientation navigation experiment.
In the experiment of mouse Morris four days orientation navigations of water maze, all mouse reach latency and the trip of platform
Swimming distance is gradually shortened.The escape latency and swimming distance of the high, medium and low dosage group mouse of composition grain become in decline
Gesture.For Model of Dementia group compared with the high, medium and low dosage group mouse escape latency of extract and swimming distance, difference has statistics
Meaning（P＜ 0.05）.
The comparison of 2 each group mouse escape latency of table（S）（n=10）
Note：Compared with normal group,△ P＜ 0.01；Compared with model group, *P0.05 * * of ＜P＜ 0.01.
Claims (12)
1. a kind of Uygur medicine composition and preparation method thereof for treating failure of memory, it is characterised in that：The Uygur medicine
Composition be made of the raw material of following weight proportion, 60~150 g of foreign fennel, 60~160 g of fennel seeds, raisins 60~
360 g, 60~160 g of rose, 60~160 g of 60~160 g of fig, 60~160 g of licorice and venushair fern.
2. a kind of Uygur medicine composition and preparation method thereof for treating failure of memory according to claim 1, special
Sign is：The Uygur medicine composition be made of the raw material of following weight proportion, 60 g of foreign fennel, 60 g of fennel seeds,
60 g of raisins, 111 g of rose, 60 g of 238 g of fig, 160 g of licorice and venushair fern.
3. a kind of Uygur medicine composition and preparation method thereof for treating failure of memory according to claim 1, special
Sign is：The Uygur medicine composition is 111 g of foreign fennel, fennel seeds 111 made of the raw material of following weight proportion
G, 238 g of raisins, 105 g of rose, 111 g of 150 g of fig, 105 g of licorice and venushair fern.
4. a kind of Uygur medicine composition and preparation method thereof for treating failure of memory according to claim 1 and 2,
It is characterized in that：The formula of the Uygur medicine composition and its extract pharmaceutically acceptable preparation is particle, syrup, cream
Side, oral solution, tablet, powder, capsule, granule and pill.
5. a kind of Uygur medicine composition and preparation method thereof for treating failure of memory according to claim 1 and 2,
It is characterized in that：The Uygur medicine composition is prepared with two methods, is as follows：
First method：Water extracting method
The first step：Appropriate foreign fennel, fennel seeds, raisins, rose, fig, licorice and iron are weighed according to aforementioned proportion
The medicinal materials such as line fern in extraction vessel plus are equivalent to the distilled water of 10 times of medicine materical crude slice weight, impregnate 30 minutes；
Second step：It decocts extraction twice, decocts extraction 60 minutes, filtering for the first time；5 times of suitable medicine materical crude slice weight is added for the second time
Distilled water is extracted 30 minutes and is filtered；
Third walks：Merging filtrate concentration, crushes granulation at spray drying；
4th step：Preparation is particle, syrup, herbal paste, oral solution, tablet, powder, capsule, granule and pill.
6. second method：Essential oil extraction method
The first step：Take foreign fennel and appropriate fennel seeds respectively according to the above ratio, add 5 ~ 15 times amount water, the way of distillation extract volatile oil 5 ~
10 hours, after volatile oil extracting, remaining Aqueous extracts filtering, filtrate was collected spare；
Second step：Volatile oil is saturated with beta-cyclodextrin, refrigerated overnight, is filtered, dry, finely ground, crosses 80 ~ 100 mesh sieve, standby
With；
Third walks：It takes raisins, rose and appropriate fig respectively according to the above ratio, is suitably ground into coarse powder, add 5 ~ 15 times
Water is measured, refluxing extraction 1 ~ 3 time is extracted 1 ~ 3 hour every time, filtering, and merging filtrate is concentrated under reduced pressure, and supercentrifugal process removal of impurities takes
Clear liquid, it is spare；
4th step：Extracting liquorice root is distinguished according to the above ratio, and appropriate venushair fern is suitably ground into coarse powder, adds 5 ~ 15 times of amounts a concentration of
55 ~ 85% ethyl alcohol, refluxing extraction 1 ~ 3 time are extracted 1 ~ 3 hour every time, filtering, and merging filtrate is spare；
5th step：Remaining aqueous solution after volatile oil, the supernatant after cleaning in third step, in the 4th step will be extracted in second
Liquid extract is concentrated under reduced pressure into ethanol extract respectively, merges liquid extract, positive sky main officer of Tibet is early, crushes, and crosses 80 ~ 100 mesh sieve, obtains medicinal extract
Powder, it is spare；
6th step：Appropriate extract powder and volatile oil saturate and lactose mixing are taken, 90% second containing 5% polyvinylpyrrolidone is added
Softwood processed is dried in vacuo, whole grain at a temperature of 55 ~ 65 DEG C, is sterilized with the sieve granulation of 14 mesh alcoholic solution in right amount；
7th step：Preparation is particle, syrup, herbal paste, oral solution, tablet, powder, capsule, granule and pill.
7. a kind of Uygur medicine composition and preparation method thereof for treating failure of memory according to claim 3, special
Sign is：Used beta-cyclodextrin, lactose, polyvinylpyrrolidone, ethyl alcohol be as《Chinese Pharmacopoeia》Defined commercial product.
8. a kind of Uygur medicine composition and preparation method thereof for treating failure of memory according to claim 3, special
Sign is：Used volatile oil saturation conditions β-CD：Volatile oil proportioning is 4:1~8:1, saturation temperature is 30 ~ 45 DEG C, when saturation
Between 1 ~ 3 hour；Volatile oil saturate drying temperature is 38 ~ 42 DEG C.
9. a kind of Uygur medicine composition and preparation method thereof for treating failure of memory according to claim 3, special
Sign is：Institute is concentrated under reduced pressure into medicinal material using Aqueous extracts:Liquid ratio is 1:3~1:10.
10. a kind of Uygur medicine composition and preparation method thereof for treating failure of memory according to claim 3, special
Sign is：Centrifuge speed is 10000 ~ 12000 revs/min when used supercentrifugal process removal of impurities, and centrifugation time is 10 ~ 20 points
Clock.
11. a kind of Uygur medicine composition and preparation method thereof for treating failure of memory according to claim 3, special
Sign is：The temperature that is concentrated under reduced pressure using each extracting solution be 60 ~ 75 DEG C, pressure is -0.09 ~ -0.07pa, is concentrated into relatively close
The liquid extract that degree is 1.20 ~ 1.25.
12. a kind of Uygur medicine composition and preparation method thereof for treating failure of memory according to claim 3, special
Sign is：Institute is to use 60Co- gamma-rays 6kGy irradiation sterilizations using sterilizing methods.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810268476.1A CN108272917A (en) | 2018-03-29 | 2018-03-29 | A kind of Uygur medicine composition and preparation method thereof for treating failure of memory |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810268476.1A CN108272917A (en) | 2018-03-29 | 2018-03-29 | A kind of Uygur medicine composition and preparation method thereof for treating failure of memory |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108272917A true CN108272917A (en) | 2018-07-13 |
Family
ID=62810898
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810268476.1A Pending CN108272917A (en) | 2018-03-29 | 2018-03-29 | A kind of Uygur medicine composition and preparation method thereof for treating failure of memory |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108272917A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115737729A (en) * | 2022-11-24 | 2023-03-07 | 新疆医科大学 | National medicinal preparation for treating osteoporosis and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101829204A (en) * | 2010-03-19 | 2010-09-15 | 新疆医科大学 | Preparation method of abnormal savda munziq granules and application thereof |
| JP2017075136A (en) * | 2015-06-08 | 2017-04-20 | ロート製薬株式会社 | Internal composition |
-
2018
- 2018-03-29 CN CN201810268476.1A patent/CN108272917A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101829204A (en) * | 2010-03-19 | 2010-09-15 | 新疆医科大学 | Preparation method of abnormal savda munziq granules and application thereof |
| JP2017075136A (en) * | 2015-06-08 | 2017-04-20 | ロート製薬株式会社 | Internal composition |
Non-Patent Citations (2)
| Title |
|---|
| 发肉克•艾哈买提: "老年性痴呆的维吾尔医诊疗规范研究", 《中国优秀硕士学位论文全文数据库医药卫生科技辑》 * |
| 穆台力甫•艾力阿吉: "试探维吾尔药/成熟剂的成熟作用与组方", 《中国民族医药杂志》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115737729A (en) * | 2022-11-24 | 2023-03-07 | 新疆医科大学 | National medicinal preparation for treating osteoporosis and preparation method thereof |
| CN115737729B (en) * | 2022-11-24 | 2023-11-03 | 新疆医科大学 | Ethnic medicine preparation for treating osteoporosis and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105920476B (en) | Traditional Chinese medicine composition for preventing and treating Alzheimer disease and preparation method thereof | |
| CN110742972B (en) | Traditional Chinese medicine composition with cognitive improvement effect and preparation method thereof and traditional Chinese medicine preparation | |
| CN104027428B (en) | Preparation method of traditional Chinese medicine compound and application of traditional Chinese medicine compound in prevention and treatment of senile dementia | |
| CN104042720A (en) | Traditional Chinese medicine for preventing and treating diabetes with depression and application of traditional Chinese medicine | |
| US20230125425A1 (en) | Traditional chinese medicine extract composition with function of regulating depressive emotion and preparation method and traditional chinese medicine preparation thereof | |
| CN108272917A (en) | A kind of Uygur medicine composition and preparation method thereof for treating failure of memory | |
| CN103735761B (en) | A kind of pharmaceutical composition preventing and treating Alzheimer disease and preparation method thereof | |
| CN100579564C (en) | Medicine for curing gout and its preparing method | |
| CN107648335B (en) | Traditional Chinese medicine composition for regulating atherosclerosis autophagy and apoptosis and preparation method thereof | |
| CN1686514A (en) | Chinese medicinal preparation for treating anxietas, depression and its production method | |
| CN101129604B (en) | Antihypelipidemic traditional Chinese medicine producing method | |
| CN110694025A (en) | Eight-treasure intelligence-benefiting compound and preparation method and application thereof | |
| CN108524583A (en) | The preparation method of radix stellariae dichotomae heat-clearing active component | |
| Szulc et al. | Influence of extracts from and on the development of alcohol tolerance in rats | |
| CN116688005B (en) | Application of pulsatilla chinensis bunge extract in preparation of drugs for treating insomnia | |
| CN116115703B (en) | Traditional Chinese medicine composition and preparation method thereof | |
| CN109498673B (en) | Traditional Chinese medicine composition and application thereof in preparation of drugs for treating AD | |
| CN114984074B (en) | Preparation method of ginseng total protein and application thereof in improving parkinsonism | |
| CN108042747B (en) | Traditional Chinese medicine composition for improving cognitive disorder and preparation method and application thereof | |
| CN116270922B (en) | Prescription for eliminating turbid pathogen, resolving masses and removing arthralgia and application thereof | |
| CN114344388B (en) | Traditional Chinese medicine composition for treating insomnia and application thereof | |
| CN108888731B (en) | Pharmaceutical composition for relieving cough and reducing sputum | |
| CN111450217A (en) | Traditional Chinese medicine composition for treating Parkinson's disease dementia and preparation method thereof | |
| CN102138982B (en) | Compound valeriana amurensis composition for treating senile dementia, and preparation method and application thereof | |
| CN114306543A (en) | Traditional Chinese medicine composition for treating Alzheimer disease and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20180713 |